Platelet-activating factor-acetylhydrolase (PLA2G7) A379V (exon 11) gene polymorphism is functionally associated with coronary artery disease severity but not the onset of acute coronary syndrome

Acta Cardiologica Sinica

Volumn 22, Issue 4, 2006, Pages 212-220

  Liu, Ping Yen ^a,b   Chung, Hsing Chun ^c   Chen, Ju Yi ^a   Lee, Cheng Han ^a   Chan, Shih Hung ^a,b   Li, Yi Heng ^a,b   Lin, Li Jen ^a   Chen, Jyh Hong ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Acute coronary syndrome; Atherosclerosis; Platelet activating factor; Polymorphism

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

ACUTE CORONARY SYNDROME; ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN FUNCTION; RISK ASSESSMENT;

EID: 33847026462     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111:980-7.
2. Karabina SA, Elisaf M, Bairaktari E, et al. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997;27:595-602.
3. Suckling KE, Macphee CH. Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque. Expert Opin Ther Targets 2002;6:309-14.
4. Kim JD, Baker CJ, Roberts RF, et al. Platelet activating factor acetylhydrolase decreases lung reperfusion injury. Ann Thorac Surg 2000;70:423-8.
5. 2. Crit Rev Immunol 1997;17:225-83.
6. 2. J Biol Chem 1994;269:13057-60.
7. Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280-4.
8. 2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003;24:1824-32.
9. Liu PY, Li YH, Wu HL, et al. Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. J Thromb Haemost 2006;4:1023-8.
10. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994→ T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in a Japanese population. Metabolism 1998;47:177-81.
11. Yamada Y, Yoshida H, Ichihara S, et al. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000;150:209-16.
12. Kruse S, Mao XQ, Heinzmann A, et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 2000;66:1522-30.
13. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. HIFMECH Study Group. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 2003;168:283-8.
14. Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 2004;13:1341-51.
15. Blankenberg S, Stengel D, Rupprecht H, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003;44:1381-6.
16. Fox KA, Birkhead J, Wilcox R, et al. British Cardiac Society Working Group. British Cardiac Society Working Group on the definition of myocardial infarction. Heart 2004;90:603-9.
17. Liu PY, Chen JH, Li YH, et al. Synergistic effect of stromelysin-I (matrix metalloproteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003;90:132-9.
18. Tsai WC, Li YH, Tsai LM, et al. Correlation of homocytsteine levels with the extent of coronary atherosclerosis in patients with low cardiovascular risk profiles. Am J Cardiol 2000;85:49-52.
19. Peris T. Genetic and environmental influences on exceptional longevity and the AGE nomogram. Ann N Y Acad Sci 2002;959:1-13.
20. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002;3:57-68.
21. Brites FD, Verona J, Schreier LE, et al. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low HDL-cholesterol levels with or without primary hypertriglyceridemia. Arch Med Res 2004;35:235-40.
22. Unno N, Nakamura T, Kaneko H, et al. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J Vasc Surg 2000;32:263-7.
23. Morgan EN, Boyle EM Jr, Yun W, et al. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 1999;100(19 Suppl):II365-8.
24. Svetlov SI, Howard KM, Debuysere MS, Olson MS. Secretory PAF-acetylhydrolase of the rat hepatobiliary system: characterization and partial purification. Am J Physiol 1998;274:G891-900.
25. Serebruany VL, Gurbel PA, Murugesan SR, et al. Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. Cardiology 1998;90:127-30.